| Description | Fentiazac（BR-700） is an orally active nonsteroidal alkanoic acid derivative with significant analgesic, anti-inflammatory, and antipyretic activity.Fentiazac is used in the study of inflammatory diseases such as rheumatoid arthritis, osteoarthritis, periodontitis, and tendonitis. |
| In vivo | Fentiazac在大鼠、猴子和狗上经过反复口服给药后表现出良好的耐受性，未观察到心脏和骨髓功能以及血液化学有显著变化。[1] |
| Synonyms | Donorest, Flogene, BR-700 |
| molecular weight | 329.8 |
| Molecular formula | C17H12ClNO2S |
| CAS | 18046-21-4 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 90 mg/mL (272.89 mM), Sonication is recommended. |
| References | 1. Marmo E. Experimental and clinical pharmacology of fentiazac, a new, non-steroidal anti-inflammatory agent. Current Medical Research and Opinion. 1979, 6(sup2): 53-63. 2. Katona G, et al. Efficacy and tolerability of fentiazac in rheumatoid arthritis: double-blind study versus indomethacin. Current Medical Research and Opinion. 1979, 6(sup2): 71-78. 3. Famaey JP, et al. Fentiazac in the treatment of osteoarthritis and tendinitis. Curr Med Res Opin. 1983;8(9):675-81. 4. Leguen MA. Single-blind clinical trial comparing use of fentiazac and paracetamol in postendodontic periodontitis. Clin Ther. 1985;7(2):145-50. |